Early Crohn's disease: can we change the disease course?

Affiliations

¹ Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers, Amsterdam, The Netherlands. g.dhaens@amsterdamumc.nl.
² Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.

Geert D'Haens et al. Nat Rev Gastroenterol Hepatol. 2025 Jun.

. 2025 Jun;22(6):367-368.

doi: 10.1038/s41575-025-01072-w.

¹ Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers, Amsterdam, The Netherlands. g.dhaens@amsterdamumc.nl.
² Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.

No abstract available

Conflict of interest statement

Competing interests: The authors declare no competing interests.

1. D’Haens, G. et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet 371, 660–667 (2008). - DOI - PubMed
1. Colombel, J.-F. et al. Effect of tight control management on Crohn’s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet 390, 2779–2789 (2017). - DOI - PubMed
1. D’Haens, G. R. et al. Vedolizumab treatment is more effective and safer in early versus late Crohn’s disease: final results of the Love-CD trial. United European Gastroenterol. J. 12, OP147 (2024).
1. Sands, B. E. et al. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn’s disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. Lancet 399, 2200–2211 (2022). - DOI - PubMed
1. Ponsioen, C. Y. et al. Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn’s disease: a randomised controlled, open-label, multicentre trial. Lancet Gastroenterol. Hepatol. 2, 785–792 (2017). - DOI - PubMed